WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 13, 2097-2109. Review Article ISSN 2277–7105

ADVANCES IN TRANSDERMAL DRUG DELIVERY: STRATEGIES TO OVERCOME THE SKIN BARRIER AND THEIR CLINICAL APPLICATION

***Divyank Agarwal, Nitin Sharma**

Asst. Prof, Amardeep College of Pharmacy.

Article Received on 05 June 2026,
Article Revised on 25 June 2026,
Article Published on 03 July 2026,

https://doi.org/10.5281/zenodo.21155747

***Corresponding Author**
Divyank Agarwal
Asst. Prof, Amardeep College of Pharmacy.

How to cite this Article: *Divyank Agarwal, Nitin Sharma (2026). Advances In Transdermal Drug Delivery: Strategies To Overcome The Skin Barrier And Their Clinical Application. World Journal of Pharmaceutical Research, 15(13), 2097-2109.

ABSTRACT

As the biggest organ in the body, the skin serves as a critical channel for transdermal medicinal interventions as well as a protective barrier. The field of skin-based medication delivery devices has advanced significantly in recent decades, radically changing how dermatological treatments are administered. Reduced bioavailability, delayed therapeutic onset, and systemic side effects are common problems with traditional administration techniques, such as injectable therapy and oral drugs. By enabling the direct application of medicinal substances at the intended site of action, skin-based delivery methods, on the other hand, offer a tempting option that minimizes systemic exposure and maximizes localized effects. Skin-based delivery systems have potential for treating systemic disorders that present with cutaneous symptoms in addition to their uses in dermatology. Dermatological symptoms are frequently present in diseases like rheumatoid arthritis, diabetes, and some types of cancer. Localized systemic treatment administration through the skin may offer a more effective and minimally intrusive method of treating these ailments. With a focus on the application of nanotechnology, microneedles, and other cutting-edge delivery techniques in dermatology, this review attempts to investigate the emerging subject of skin-based delivery systems for therapeutic compounds.

KEYWORDS: Drug Administration, Transdermal Drug Delivery, Skin-Based Therapies, Nanotechnology and Therapeutic Agents.

1. INTRODUCTION

Treating a variety of dermatological disorders is made extremely difficult by the stratum corneum, the skin's outermost layer, which acts as a strong barrier that prevents medications from being absorbed transdermally at effective concentrations. Achieving appropriate drug levels in the systemic circulation is essential for the successful treatment of conditions like psoriasis, eczema, and acne. Chemical enhancers have been investigated by researchers as a way to increase absorption; however their use has been associated with negative reactions and decreased patient compliance.[1] These problems demonstrate the need for more sophisticated, patient-friendly techniques to enhance medication administration through the skin, especially for people with long-term skin disorders. Furthermore, emulsifying highly lipid-soluble medications is made more difficult by the structural makeup of the epidermis, which is composed of lipid-dense extracellular matrix and protein-rich cellular structures. When treating diseases like atopic dermatitis, where the skin barrier is naturally weakened, and this difficulty is particularly pertinent.[2] Optimizing transdermal formulations that can deliver medicines for dermatological applications requires understanding in go how drug characteristics and skin composition interact. The stratum corneum's lipids are essential for stopping transepidermal water loss, which prevents hydrophilic medications from penetrating the epidermal layers.[3] In addition to maintaining the integrity of the skin, this dual role makes it more difficult to administer the therapeutic substances required for the successful treatment of ailments like psoriasis and acne. Improving the effectiveness and dependability of transdermal therapeutic delivery systems aimed at dermatological illnesses requires overcoming these complex physiological hurdles. Unlocking the full potential of this medication delivery route in dermatology will require ongoing research and innovation in formulation technologies and penetration augmentation tactics.

One of the most important advancements in precise intracellular pharmaceutical delivery, especially for dermatological disorders requiring targeted intervention, is nanotechnology. The science of creating materials at the molecular and anatomic levels, known as nanotechnology, enables the creation of structures in at least one dimension that are approximately in the 1–100 nm size range.[4] Many novel medical therapies that were previously unthinkable have been made available by the development of technology of this magnitude. Lipid systems like Liposomes and micelles, which can contain inorganic nanoparticles like gold, were part of the first generation of nanoparticles that the FDA allowed.[5]



Fig.1: Diagrammatic illustration of the parts and uses of transdermal drug delivery systems.

2. SKIN-BASED DRUG DELIVERY AND NANOTECHNOLOGY

In dermatology, nanotechnology is essential for improving the effectiveness of skin-based medication delivery systems. Conventional liposomes, PEGylated liposomes, ligand-targeted liposomes, and there an optic liposomes are the four primary liposome types now used for dermatological purposes.[6] Traditional liposomes have an aqueous core surrounded by a lipid bilayer made of anionic, cationic, or neutral lipids, mostly cholesterol and phospholipids. Hydrophobic or hydrophilic materials can fill the lipid bilayer and the aqueous core, respectively.[7,8] These liposomes can be used in dermatological applications to encapsulate therapeutic substances like corticosteroids, antibiotics, or anti-inflammatory medications, enabling localized therapy of skin disorders like acne, psoriasis, or eczema. Polyethylene glycol (PEG) is affixed to the surface of PEGylated liposomes, which improve stability and decrease the possibility of immune system recognition.[9] This characteristic is very helpful in dermatological Treatments since it prolongs the drug's stay on the skin's surface, allowing for longer- lasting Therapeutic benefits while reducing systemic exposure. It is possible to create ligand targeted liposomes containing particular ligands that can attach toskin specific receptors such as peptides, carbohydrates, or antibodies.[10] For diseases like Psoriasis, which affect particular skin cells, this tailored delivery strategy is beneficial. Treatment efficacy can

be greatly increased while minimizing off-target consequences by accurately administering medications to these target cells. By combining nanoparticles with elements for targeting, imaging, and therapy, the agnostic liposomes integrate features of the preceding three categories.[11, 12] These liposomes can be extremely useful in dermatology for both therapeutic and diagnostic applications. For example, they can transport therapeutic medicines directly to the location while also enabling real-time imaging of skin diseases.

Self-delivery and passive delivery are the two main medication delivery mechanisms made possible by nanoparticles. Drugs are incorporated into the interior chamber of the nanoparticle through hydrophobic interactions in passive delivery.[13, 14] In dermatology, this technique Guarantee targeted drug release at the application site, which is essential for successfully Treating localized skin disorders. More medications can be loaded onto then a no particle through self-delivery, which is the conjugation of pharmaceuticals to a carrier.[15] However, exact Control over drug release is essential when treating dermatological conditions in order to avoid Side effects related to systemic absorption. Transdermal medication delivery using microemulsions has demonstrated considerable promise.[16]



Fig.2 The skin's structural layers and the depth of penetration needed for particular applications are highlighted in the diagram.

For dermatological applications, incorporating medicinal compounds into liposomes or nanoparticles has shown numerous benefits. Improved stability is one significant advantage, especially for nucleic acid therapeutic agents, which can be brittle and prone to deterioration.[17, 18] Delivering gene treatments or mRNA vaccinations intended to successfully treat skin diseases or disorders requires this protection. Additionally, liposomes

are efficient transporters of nucleic acids such as siRNA or mRNA, which can enhance the effectiveness of gene therapy for skin disorders by improving cellular uptake.[19]

For diseases like skin cancer, where precise gene delivery can change the course of the disease, this trait is essential. Additionally, using liposomes or nanoparticles can increase patient tolerance. When treating skin disorders, avoiding metabolism from the gastrointestinal tract might help reduce nausea and gastrointestinal distress caused by oral drugs, which are typical adverse drug reactions (ADRs). Better patient adherence and treatment results may result from this enhancement. Moreover, encasing biologics in liposomes or nanoparticles may lessen immunogenicity, improving the body's uptake of them and reducing side effects.[20, 21] This decrease in immunogenic reactions is particularly helpful in the treatment of long-term dermatological conditions, improving the general health and well-being of patients.

3. CHALLENGES IN NANOTECHNOLOGIES IN TRANSDERMAL DRUG DELIVERY SYSTEM

The use of nanoparticles in dermatological contexts is still largely neglected despite major advances in medical technology, indicating a clear gap between research and practical application. Because of their special qualities, such as increased surface area and improved interaction with biological systems, nanoparticles present promising treatments for a range of complex skin conditions.[22] For example, their capacity to reach deeper skin layers may enhance the effectiveness of topical therapies for ailments including psoriasis, eczema, and acne. Finding safe, dependable, and efficient medication delivery strategies that limit side effects while simultaneously improving treatment results for skin disorders is one of dermatology's biggest difficulties.[23] When creating treatments based on nanoparticles, it is crucial to take into account the delicate nature of the skin microbiome as well as the possibility of irritation or allergic reactions. Customizing the size and surface properties of nanoparticles may improve their compatibility with skin tissues, which would increase patient acceptance and treatment compliance.[24]

Technical problems including stability, which impacts the shelf life and efficacy of nanoparticle formulations, particularly in topical therapies, are the main barriers to the extensive clinical use of nanoparticles in dermatology.[25] To guarantee that therapeutic substances are delivered at the ideal rate and concentration for skin absorption, the drug release profiles must also be adjusted. Because dermatological applications frequently require

thorough research to demonstrate safety and efficacy on human skin, regulatory constraints represent significant obstacles to bringing these new medicines to market.[26] Investigating the potential of nanotechnologies in treating complicated dermatological disorders is essential despite these challenges. Treatment paradigms could be completely changed by creative methods like adding nanoparticles to cosmetic formulations or utilizing them to improve the delivery of biologics for diseases like skin cancer and atopic dermatitis. Lastly, to overcome the obstacles and realize the full potential of nanotechnologies in dermatology, continued cooperation between researchers, dermatologists, and regulatory agencies is crucial.

4. SKIN-BASED DRUG DELIVERY IN DERMATOLOGY

The complex structural characteristics of human skin make managing chronic dermatological conditions including psoriasis, dermatitis, and acne particularly difficult. As the outermost layer, the stratum corneum serves as a protective barrier that severely restricts the entry of therapeutic medicines needed to treat various disorders. Due to their incapacity to efficiently distribute medications to the deeper layers of the skin where they are most needed, traditional topical therapies, such as creams, ointments, and gels, frequently fail to produce consistent clinical results.[27] However, by removing these obstacles, the development of sophisticated drug delivery methods like liposomes, microneedles, and nanoemulsions is revolutionizing dermatological treatment.

In dermatology, nanoemulsions have become a revolutionary way to improve medication administration, especially when it comes to psoriasis. Nanoemulsions enable better medication deposition directly in psoriatic lesions and thicker plaques due to their small droplet size and enhanced solubility.[28] In addition to improving therapeutic results, this tailored strategy lowers the possibility of systemic adverse effects, which is a major benefit for treating chronic skin disorders. By successfully penetrating the stratum corneum's lipid matrix, these nanoscale carriers can provide localized distribution while reducing systemic absorption.[29] The Nano emulsion's function in dissolving the stratum corneum's lipid matrix in particular, targeted regions accounts for the increased efficacy. Greater interaction with skin cells is made possible by the nano emulsion droplets higher surface area, which raises the therapeutic chemicals overall absorption. These characteristics reduce systemic exposure while delivering higher medication concentrations directly to psoriatic lesions when compared to conventional therapy.

Additionally, micro needling is a medication delivery method for the treatment of long-term

dermatological conditions. By circumventing the skin's natural barrier, microneedling increases the effectiveness of the therapeutic agents' activity through microchannels that enable the delivery of medications into deeper layers. Microneedling is a safe and effective treatment for acne vulgaris, according to research by Alquam et al. that was published in Skin Health and Disease. Microneedling has the potential to be a successful treatment for chronic skin problems, as evidenced by the study's significant decrease in acne lesions and low post-treatment complications.[30] This enhances patient happiness in addition to improving treatment outcomes. Additionally, a study conducted by Lima et al. compared the efficacy of topical medications alone against microneedling in treating chronic melasma. Microneedling greatly increases the efficacy of conventional topical treatments, according to the results, which showed that the combination treatment produced notable clinical and histologic benefits.[31] These findings point to a higher potential for its use as a flexible and successful adjuvant treatment for long-term dermatological conditions. Microneedling shows promise for innovation in the emerging field of skin-based medicine delivery, even though research into its applications is still ongoing.

5. ENHANCED PATIENT OUTCOMES

The effectiveness of traditional therapy for dermatological disorders is limited, and they currently come at the expense of repeated applications, poor outcomes, and unpleasant or even uncomfortable feelings. This has become an increasing problem, however with the development of sophisticated skin-based drug delivery systems, cutting-edge technology has steadily improved to improve treatment efficacy, reduce side effects, and boost patient adherence. Thanks to sophisticated drug delivery systems, therapeutic medications today have greater remedial efficacy and may sustain steady, extended activity. For instance, hydrogels for eczema enable a sustained release of corticosteroids to prevent flare-ups and maintain constant symptom control.[32] by creating a wet protective layer over the skin, hydrogel's special mechanism improves drug penetration and replenishes the area with moisture. Longer periods of remission are the outcome of this dual benefit, which improves drug penetration and lowers flare-ups. By Providing efficient, user-friendly solutions designed for chronic diseases, significantly enhance patients' quality of life beyond merely treating symptoms.

Such advance



Fig. 3 Applications cover a wide range of fields, including as general pharmacological interventions, cancer treatment, hormone therapy, ophthalmic drug delivery, vaccine administration, and pain management.

The goal of skin-based medication delivery systems has also been to reduce the adverse effects of medicinal substances. Conventional therapies frequently cause medications to be absorbed systemically, which might have undesirable side effects. Corticosteroids are encapsulated by new.

Technology, such as liposomal formulations, which minimize their potential for systemic absorption while preserving their anti-inflammatory effectiveness.[33] Solid lipid nanoparticles (SLN) also lessened the irritation usually associated with conventional formulations in acne treatments. SLNs minimize skin dryness, redness, and peeling by delivering therapeutic drugs to sebaceous glands steadily and locally by slowing the rapid release of active chemicals.[34] Patients are more likely to stick with therapy when they experience less side effects thanks to these administration modalities, which also greatly increase patient comfort and promote adherence to treatment plans.[35]

The treatment of chronic dermatological disorders has advanced significantly with the use of sophisticated skin-based medication delivery devices. Modern technology provides more focused, long-lasting, and efficient drug administration by overcoming the drawbacks of conventional treatments. Hydrogels, liposomal formulations, and solid lipid nanoparticles are examples of innovations that improve patient outcomes and quality of life by offering localized treatment with fewer side effects. These technologies have enormous potential to further transform dermatology as research advances, opening the door to more individualized, effective, and patient-centered methods of treating skin conditions.[36]

6. STABILITY AND OPTIMIZATION

Because of their ease of self-administration, safety, patient compliance, and dosage flexibility, oral delivery systems are the most popular way to dispense medications. Poor stability in the gastrointestinal tract's acidic conditions is one of its drawbacks, albeit.[37] Intravenous injection distribution was created as an alternate route since oral medications frequently have inadequate absorption. IV injections avoid hepatic metabolism and are 100% accessible, in contrast to oral medications. Nevertheless, patients may not always tolerate this painful and intrusive procedure.[38] Because they are less intrusive, avoid metabolic processes, and require less frequent administration, skin-based delivery methods offer a viable option. By acting on the skin's outer layer, liposomes serve as drug localizers; however, their increased size, stiffness, and decreased stability frequently prevent them from penetrating deeper into the skin. Transfersomes, on the other hand, provide improved permeability; nevertheless, because their penetration depends on the water gradient, they are difficult to load with hydrophobic medicines and present difficulties when utilized in occlusive situations.[39] Optimizing nanocarriers will be essential to overcoming these constraints and improving therapeutic results as research into skin-based drug delivery systems progresses.

CONCLUSION

Transdermal absorption barriers have made it difficult to treat a variety of dermatological disorders. Most medicinal compounds are difficult to absorb because of the skin's protective function. The inability to administer drugs to the deeper layers of the skin is one of the main therapy challenges, leading to primarily superficial treatment of dermatological conditions. For psoriasis, eczema, and acne to significantly improve, systemic absorption is necessary. These difficulties highlight the need for novel approaches that get around current therapy

obstacles. In order to maximize treatment, novel approaches should highlight how pharmacological qualities interact with the skin. Nanotechnologies and microneedling are examples of emerging therapies that show promise for successfully overcoming these challenges. Nanotechnologies and microneedling are important means of administering skin-based treatment for long-term illnesses. Because they can offer patient-friendly treatments for skin problems, nanoparticles show great promise. Increased stability form or effective gene therapy administration, improved nucleic acid uptake, and greater patient tolerance through gastrointestinal tract metabolism bypass are just a few of the benefits that nanoparticles have demonstrated. Furthermore, encasing biologics in liposomes or nanoparticles can lessen immunological responses, increasing the body's acceptance of them and reducing side effects. Both the general health of patients and the management of chronic dermatological disorders are improved by these advantages. This method offers a minimally invasive alternative that is particularly helpful for chronic illnesses requiring long-term adherence by facilitating the effective distribution of both hydrophilic and lipophilic medicines. Additionally, microneedling improves therapeutic responses in inflammatory illnesses and boosts vaccine efficiency by utilizing the skin's immunological qualities.

Skin-based delivery systems have advanced creatively, but there is still little clinical use for them. To close the gaps and overcome the obstacles that prevent these breakthroughs from being implemented in clinical practice, more research and cooperation are essential. Patient outcomes in dermatology could be significantly improved by steady advancements in nanotechnology, microneedles, and other cutting-edge delivery technologies. Further innovation in formulation strategies and penetration improvement techniques is essential to fully utilize these technologies. Overcoming obstacles and guaranteeing the successful integration of nanotechnologies into dermatology practice will require cooperation between researchers, dermatologists, and regulatory agencies. In the end, improving these systems will open the door to more individualized, effective, and patient-focused methods of treating skin conditions.

REFERENCES

1. Prausnitz MR, Mitragotri S, Langer R. (2004). Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov, 3(2): 115-124.
2. Baroni A, Buommino E, De Gregorio V, Ruocco E, Ruocco V, Wolf R. (2012). Structure and function of the epidermis related to barrier properties. Clin Dermatol, 30(3): 257-262.

3. Farokhzad OC, Langer R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1): 16-20.
4. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. (2018). Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology, 16(1): 71.
5. Hussan Reza KH, Baid CL. (2011). Nanoemulsion as a Novel Transdermal Drug Delivery System. International Journal of Pharmaceutical Sciences and Research, 2(8): ISSN: 0975-8232.
6. Debnath S, Pramanik S, Seth D, Mukerjee N, Ng JC, Awuah WA, et al. (2025). Emerging nanotechnologies in drug delivery: Insights and regulatory challenges. Essential Guide to Neurodegenerative Disorders, 377-395.
7. Prausnitz MR, Langer R. (2008). Transdermal drug delivery. Nat Biotechnol, 26(11): 1261-1268.
8. Bilal M, Mehmood S, Raza A, Hayat U, Rasheed T, Iqbal HMN. (2021). Microneedles in Smart Drug Delivery. Adv Wound Care (New Rochelle), 10(4): 204-219.
9. Jaiswal S, Jawade S. (2024). Microneedling in Dermatology: A Comprehensive Review of Applications, Techniques, and Outcomes. Cureus, 16(9): e70033.
10. Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, et al. (2019). Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother, 109: 1249-1258.
11. Kim YC, Park JH, Prausnitz MR. (2012). Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev, 64(14): 1547-1568.
12. Ita K. (2017). Dissolving microneedles for transdermal drug delivery: Advances and challenges. Biomed Pharmacother, 93: 1116-1127.
13. Ingrole RSJ, Gill HS. (2019). Microneedle Coating Methods: A Review with a Perspective. J Pharmacol Exp Ther, 370(3): 555-569.
14. Menon I, Bagwe P, Gomes KB, Bajaj L, Gala R, Uddin MN, et al. (2021). Microneedles: A New Generation Vaccine Delivery System. Micromachines (Basel), 12(4): 435.
15. Yepes-Nunez JJ, Guyatt GH, Gomez-Escobar LG, Perez-Herrera LC, ChuA WL, Ceccaci R, et al. (2023). Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol, 151(1): 147-158.
16. Zhang M, Qin X, Gao Y, Liang J, Xiao D, Zhang X, et al. (2023). Transcutaneous Immunotherapy for RNAi: A Cascade-Responsive Decomposable Nanocomplex Based on Polyphenol-Mediated Framework Nucleic Acid in Psoriasis. Adv Sci (Weinh), 10(33):

e2303706.

17. Dahri M, Beheshtizadeh N, Seyedpour N, Nakhostin-Ansari A, Aghajani F, Seyedpour S, et al. (2023). Biomaterial-based delivery platforms for transdermal immunotherapy. Biomed Pharmacother, 165: 115048.
18. Shrestha N, Karve T, Kipping T, Banga AK. (2024). Fabrication of Poly Lactic-*co*-Glycolic Acid Microneedles for Sustained Delivery of Lipophilic Peptide-Carfilzomib. Mol Pharm, 21(10): 5192-5204.
19. Hamed R, Abu Nahia BJ, Alkilani AZ, Al-Adhami Y, Obaidat R. (2024). Recent Advances in Microneedling-Assisted Cosmetic Applications. Cosmetics, 11(2): 51.
20. Ito Y, Yoshimura M, Tanaka T, Takada K. (2012). Effect of lipophilicity on the bioavailability of drugs after percutaneous administration by dissolving microneedles. J Pharm Sci, 101(3): 1145-1156.
21. Suh H, Shin J, Kim YC. (2014). Microneedle patches for vaccine delivery. Clin ExpVaccine Res, 3(1): 42-49.
22. Amani H, Shahbazi MA, D'Amico C, Fontana F, Abbaszadeh S, Santos HA. (2021). Microneedles for painless transdermal immunotherapeutic applications. J Control Release, 330: 185-217.
23. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, et al. (2012). Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep, 2: 357.
24. Mistilis MJ, Joyce JC, Esser ES, Skountzou I, Compans RW, Bommarius AS, et al. (2017). Long-term stability of influenza vaccine in a dissolving microneedle patch. Drug Deliv Transl Res, 7(2): 195-205.
25. Hong Y, Yu H, Wang L, Chen X, Huang Y, Yang J, Ren S. (2022). Transdermal Insulin Delivery and Microneedles-based Minimally Invasive Delivery Systems. Curr Pharm Des, 28(39): 3175-3193.
26. Li W, Terry RN, Tang J, Feng MR, Schwendeman SP, Prausnitz MR. (2019). Rapidly separable microneedle patch for the sustained release of a contraceptive. Nat Biomed Eng, 3(3): 220-229.
27. Raszewska-Famielec M, Flieger J. (2022). Nanoparticles for Topical Application in the Treatment of Skin Dysfunctions-An Overview of Dermo-Cosmetic and Dermatological Products. Int J Mol Sci, 23(24): 15980.
28. Dinshaw IJ, Ahmad N, Salim N, Leo BF. (2021). Nanoemulsions: A Review on the Conceptualization of Treatment for Psoriasis Using a 'Green' Surfactant with Low-Energy

Emulsification Method. Pharmaceutics, 13(7): 1024.

29. Dos Santos Ramos MA, DaSilva PB, Spósito L, DeToledo LG, Bonifácio BV, Rodero CF, et al. (2018). Nanotechnology-based drug delivery systems for control of microbial bio films: a review. Int J Nanomedicine, 13: 1179-1213.
30. Alqam ML, Jones BC, Hitchcock TM. (2023). Studyto determine the safety and efficacyof microneedling as an effective treatment for acne vulgaris. Skin Health Dis, 3(5): e264.
31. Lima EVA, Lima MMDA, Paixão MP, Miot HA. (2017). Assessment of the effects of skin microneedling as adjuvant therapy for facial melasma: a pilot study. BMC Dermatol, 17(1): 14.
32. Alkilani AZ, McCrudden MT, Donnelly RF. (2015). Transdermal Drug Delivery:Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics, 7(4): 438-470.
33. Metselaar JM, Storm G. (2005). Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv, 2(3): 465-476.
34. Layegh P, Mosallaei N, Bagheri D, Jaafari MR, Golmohammadzadeh S. (2013). The efficacy of Isotretinoin-loaded solid lipid nanoparticles in comparison to Isotrex® on acne treatment. Nanomedicine Journal, 1(1): 38-47.
35. Draelos ZD, Feldman SR, Berman B, Olivadoti M, Sierka D, Tallman AM, et al. (2019). Tolerability of Topical Treatments for Atopic Dermatitis. Dermatol Ther(Heidelb), 9(1): 71-102.
36. Zuo Y, Sun R, Del Piccolo N, Stevens MM. (2024).Microneedle-mediated nanomedicine to enhance therapeutic and diagnostic efficacy. Nano Converg, 11(1): 15.
37. Pawar K. (2017). Microneedles-based devices: Regulatory insights. Journal of Pharmaceutics & Drug Delivery Research, 6(1): e102.
38. Gorantla S, Dabholkar N, Sharma S, Rapalli VK, Alexander A, Singhvi G. (2021). Chitosan-based microneedles as a potential platform for drug delivery through the skin: Trends and regulatory aspects. Int J Biol Macromol, 184: 438-453.
39. Chu S, Foulad D P, Atana s kova Mesin kovska N.(2021). Safety Profile for Microneedling: A Systematic Review. Dermatol Surg, 47(9): 1249-1254.